Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibacterials süsteemseks kasutamiseks, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 ja 5. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Էստոնիա - էստոներեն - Ravimiamet

lavet pharmaceuticals ltd. - tiamuliin - suukaudse lahuse graanulid - 364,2mg 1g 1000g 1tk; 364,2mg 1g 5000g 1tk

Էստոնիա - էստոներեն - Ravimiamet

lavet pharmaceuticals ltd. - karprofeen - tablett - 100mg 20tk; 100mg 100tk; 100mg 200tk

Էստոնիա - էստոներեն - Ravimiamet

lavet pharmaceuticals ltd. - karprofeen - tablett - 50mg 100tk; 50mg 200tk; 50mg 20tk

Էստոնիա - էստոներեն - Ravimiamet

lavet pharmaceuticals ltd. - doksütsükliin - suukaudse lahuse pulber - 400mg 1g 10000g 1tk; 400mg 1g 1000g 1tk; 400mg 1g 5000g 1tk

Էստոնիա - էստոներեն - Ravimiamet

lavet pharmaceuticals ltd. - amoksitsilliin - suukaudse lahuse pulber - 1000mg 1g 100g 1tk

Էստոնիա - էստոներեն - Ravimiamet

lavet pharmaceuticals ltd. - karprofeen - tablett - 20mg 20tk; 20mg 100tk

Էստոնիա - էստոներեն - Ravimiamet

sanofi pasteur - kollapalaviku tekitaja, elus, nõrgestatud - süstesuspensiooni pulber ja lahusti süstlis - 1annus 0.5ml 0.5ml 20tk; 1000rÜ 10tk; 1000rÜ 1tk; 1000rÜ 20tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - muud antihypertensives - ravi pulmonaalse arteriaalse hüpertensiooni (pah) parandada koormustaluvust ja maailma terviseorganisatsiooni (who) iii funktsionaalse klassi patsientidel sümptomid. efektiivsust on näidatud:primaarse (idiopaatilise ja perekondlik) pah;pah teisejärguline skleroderma ilma märkimisväärse interstitsiaalne kopsuhaigus;pah seotud kaasasündinud süsteemne--suhu lükkab ja eisenmenger ' füsioloogia. mõned täiustused on ka näidanud patsientidel pah who funktsionaalse klassi ii. stayveer on ka märgitud arvu vähendada uue digitaalse haavandid patsientidel süsteemne multiplex ja pidev digital-haavand haigus.